FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016495342> ?p ?o ?g. }

• W3016495342 abstract "About 75% of all breast cancers are hormone receptor-positive (HR+).However, the efficacy of endocrine therapy is limited due to the high rate of either pre-existing or acquired resistance. In this work we reconstructed the pathways around oestrogen receptor (ER), mTOR and cyclin D in order to compare the effects of CDK4/6 and PI3K/AKT/mTOR inhibitors. A positive feedback loop links mTOR and ER that support each other. We subsequently considered whether a combined or sequential inhibition of CDK4/6 and PI3K/AKT/mTOR could ensure better results. Studies indicate that inhibition of CDK4/6 activates mTOR as an escape mechanism to ensure cell proliferation. In literature, the little evidence dealing with this topic suggests that pre-treatment with mTOR pathway inhibitors could prevent or delay the onset of CDK4/6 inhibitor resistance. Additional studies are needed in order to find biomarkers that can identify patients who will develop this resistance and in whom the sensitivity to CDK4/6 inhibitors can be restored." @default.
• W3016495342 created "2020-04-24" @default.
• W3016495342 creator A5002239598 @default.
• W3016495342 creator A5013502432 @default.
• W3016495342 creator A5015279553 @default.
• W3016495342 creator A5021477463 @default.
• W3016495342 creator A5026300777 @default.
• W3016495342 creator A5030533194 @default.
• W3016495342 creator A5040616139 @default.
• W3016495342 creator A5043506279 @default.
• W3016495342 creator A5048165263 @default.
• W3016495342 creator A5054063272 @default.
• W3016495342 creator A5062866803 @default.
• W3016495342 creator A5063109707 @default.
• W3016495342 creator A5063959180 @default.
• W3016495342 creator A5088184893 @default.
• W3016495342 date "2020-04-15" @default.
• W3016495342 modified "2023-10-14" @default.
• W3016495342 title "Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications" @default.
• W3016495342 cites W1967315119 @default.
• W3016495342 cites W1985389450 @default.
• W3016495342 cites W1993109993 @default.
• W3016495342 cites W1997006452 @default.
• W3016495342 cites W2009504099 @default.
• W3016495342 cites W2014001512 @default.
• W3016495342 cites W2016450639 @default.
• W3016495342 cites W2031131661 @default.
• W3016495342 cites W2057272791 @default.
• W3016495342 cites W2064086110 @default.
• W3016495342 cites W2078049733 @default.
• W3016495342 cites W2089738145 @default.
• W3016495342 cites W2102004296 @default.
• W3016495342 cites W2113458582 @default.
• W3016495342 cites W2115950635 @default.
• W3016495342 cites W2117357260 @default.
• W3016495342 cites W2154626333 @default.
• W3016495342 cites W2161551022 @default.
• W3016495342 cites W2295971206 @default.
• W3016495342 cites W2309969893 @default.
• W3016495342 cites W2397317955 @default.
• W3016495342 cites W2400091886 @default.
• W3016495342 cites W2535462468 @default.
• W3016495342 cites W2593997731 @default.
• W3016495342 cites W2736268922 @default.
• W3016495342 cites W2745695523 @default.
• W3016495342 cites W2760867470 @default.
• W3016495342 cites W2790152406 @default.
• W3016495342 cites W2793671087 @default.
• W3016495342 cites W2794558033 @default.
• W3016495342 cites W2799473358 @default.
• W3016495342 cites W2887760870 @default.
• W3016495342 cites W2902401096 @default.
• W3016495342 cites W2903599006 @default.
• W3016495342 cites W2908069836 @default.
• W3016495342 cites W2981121574 @default.
• W3016495342 doi "https://doi.org/10.3389/fgene.2020.00349" @default.
• W3016495342 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7174681" @default.
• W3016495342 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32351542" @default.
• W3016495342 hasPublicationYear "2020" @default.
• W3016495342 type Work @default.
• W3016495342 sameAs 3016495342 @default.
• W3016495342 citedByCount "8" @default.
• W3016495342 countsByYear W30164953422020 @default.
• W3016495342 countsByYear W30164953422021 @default.
• W3016495342 countsByYear W30164953422023 @default.
• W3016495342 crossrefType "journal-article" @default.
• W3016495342 hasAuthorship W3016495342A5002239598 @default.
• W3016495342 hasAuthorship W3016495342A5013502432 @default.
• W3016495342 hasAuthorship W3016495342A5015279553 @default.
• W3016495342 hasAuthorship W3016495342A5021477463 @default.
• W3016495342 hasAuthorship W3016495342A5026300777 @default.
• W3016495342 hasAuthorship W3016495342A5030533194 @default.
• W3016495342 hasAuthorship W3016495342A5040616139 @default.
• W3016495342 hasAuthorship W3016495342A5043506279 @default.
• W3016495342 hasAuthorship W3016495342A5048165263 @default.
• W3016495342 hasAuthorship W3016495342A5054063272 @default.
• W3016495342 hasAuthorship W3016495342A5062866803 @default.
• W3016495342 hasAuthorship W3016495342A5063109707 @default.
• W3016495342 hasAuthorship W3016495342A5063959180 @default.
• W3016495342 hasAuthorship W3016495342A5088184893 @default.
• W3016495342 hasBestOaLocation W30164953421 @default.
• W3016495342 hasConcept C121608353 @default.
• W3016495342 hasConcept C126322002 @default.
• W3016495342 hasConcept C29537977 @default.
• W3016495342 hasConcept C502942594 @default.
• W3016495342 hasConcept C51853150 @default.
• W3016495342 hasConcept C530470458 @default.
• W3016495342 hasConcept C55493867 @default.
• W3016495342 hasConcept C62112901 @default.
• W3016495342 hasConcept C62478195 @default.
• W3016495342 hasConcept C71924100 @default.
• W3016495342 hasConcept C75217442 @default.
• W3016495342 hasConcept C82495950 @default.
• W3016495342 hasConcept C84606932 @default.
• W3016495342 hasConcept C86554907 @default.
• W3016495342 hasConcept C86803240 @default.
• W3016495342 hasConcept C95444343 @default.
• W3016495342 hasConceptScore W3016495342C121608353 @default.
• W3016495342 hasConceptScore W3016495342C126322002 @default.
• W3016495342 hasConceptScore W3016495342C29537977 @default.

• next